This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

PTI-601

Pain Therapeutics, Inc.

Drug Names(s): combination: tramadol and low-dose naltrexone

Description: PTI-601 is a combination of tramadol and low-dose naltrexone.

Tramadol is a centrally acting analgesic. Although its mode of action is not completely understood, several complementary mechanisms appear applicable: mild agonism of parent and M1 metabolite to µ-opioid receptors, weak inhibition of reuptake of norepinephrine and serotonin, and modulation of the GABAergic system.

Naltrexone is an opioid antagonist. The company believes that a very low-dose of an opioidantagonist can enhance pain relief, reduce adverse side-effects and attenuate the development of tolerance and addiction.


PTI-601 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug